SupplementWise
Back to Blog
Research Explained 3 min readInvalid Date

Omega-3 (EPA vs. DHA): What the Clinical Research Reveals

We break down the science of fatty acids: how EPA fights inflammation and DHA supports your brain, plus the truth about the 'Omega-3 Index'.

omega-3 heart-health dha epa inflammation
SW
SupplementWise Research Team

Pharmacists & Nutrition Researchers

Not All Fats Are Created Equal

Omega-3 fatty acids are "essential," meaning your body cannot make them—you must eat them. While plant-based Omega-3s (ALA) found in walnuts and flaxseeds are healthy, research shows the conversion rate to the active forms—EPA and DHA—is less than 5% in humans [1].

To get the clinical benefits, research suggests you need to supplement with the "pre-converted" forms usually found in marine oils.

EPA: The "Body" Molecule

Eicosapentaenoic acid (EPA) is the primary anti-inflammatory workhorse.

The Research Findings:

  • Inflammation: A 2019 meta-analysis showed that higher doses of EPA are significantly more effective at lowering C-Reactive Protein (CRP) than DHA alone [3].
  • Heart Health: Landmark trials like REDUCE-IT demonstrated that high-dose purified EPA reduced the risk of cardiovascular events by 25% in high-risk patients [1].
  • Mood: Research indicates that Omega-3 supplements with a higher ratio of EPA to DHA (at least 2:1) are more effective at improving symptoms of depression.

DHA: The "Brain" Molecule

Docosahexaenoic acid (DHA) is a structural fat. It makes up a massive percentage of your brain’s cerebral cortex and the retina in your eyes.

The Research Findings:

  • Brain Architecture: DHA is critical for maintaining the "fluidity" of brain cell membranes. It allows signals to pass between neurons more quickly [2].
  • Cognitive Decline: Longitudinal studies suggest that individuals with higher blood levels of DHA have a lower risk of developing age-related cognitive decline and Alzheimer’s.
  • Pregnancy: Clinical guidelines emphasize DHA for fetal brain and eye development during the third trimester.

The Omega-3 Index: The "Hidden" Metric

How do you know if your supplement is working? Researchers use the Omega-3 Index. This measures the percentage of EPA and DHA in your red blood cell membranes.

  • High Risk: < 4%
  • Optimal Health: > 8%

In the Indian context, where vegetarianism is common and fish consumption is often localized to coastal regions, many urban Indians test in the "High Risk" zone (below 4%) [1].

Bottom line: If your goal is to lower inflammation, look for a supplement high in EPA. If your goal is memory and eye health, prioritize DHA.

The "Rancidity" Factor in Research

One reason some Omega-3 studies show mixed results is "oxidized" oil. Omega-3s are chemically unstable. Research shows that taking rancid (oxidized) fish oil can actually increase inflammation rather than decrease it.

Research Tip: Always look for a TOTOX (Total Oxidation) score on a product's third-party lab report. If the oil smells strongly "fishy" or causes "fish burps," it is likely oxidized.

How to Take It for Maximum Absorption

Clinical data shows that taking Omega-3 on an empty stomach results in poor absorption. Because these are fats, they require the presence of other fats and bile to be absorbed.

The Strategy: Take your Omega-3 with your largest meal of the day. This can increase absorption by up to 300% compared to taking it on an empty stomach.

Verdict: The "2-Gram" Rule

While the "Recommended Daily Allowance" (RDA) is low, most clinical research showing significant health outcomes uses doses of 2,000mg to 3,000mg of combined EPA/DHA per day. For most standard capsules, this means taking 2–3 pills daily, not just one.

Related Compounds

Amazon links use our affiliate tag. Learn how we select products.

References

[1]

Omega-3 Fatty Acids and Cardiovascular Disease: Current State of the Evidence

2017

DOI: 10.1161/CIR.0000000000000484
[2]

DHA and the Developing Central Nervous System

2011

DOI: 10.1016/j.plefa.2011.04.017
[3]

A meta-analysis of the effects of EPA and DHA on inflammatory markers

2019

DOI: 10.1016/j.atherosclerosis.2019.01.012